RadNet, Inc. — Q1 2015 Form 10-Q
Reporting period: Three months ended March 31, 2015; comparison is Q1 2014 unless otherwise noted. RadNet provides outpatient diagnostic imaging services and operated 259 centers, directly or through joint ventures, across seven states. Financial figures below are in U.S. dollars; “million” values are rounded.
Financial performance
| Metric | Q1 2015 | Q1 2014 | Change / context |
|---|---|---|---|
| Total net revenue | $181.3 million | $168.9 million | Up 7.3% |
| Net service fee revenue | $157.6 million | $151.9 million | Up 3.7%; includes provision for bad debts |
| Revenue under capitation arrangements | $23.7 million | $17.0 million | Up 39.4%; same-center growth was 34.0%, mainly from new and expanded private-insurer contracts |
| Provision for bad debts | $7.5 million | $6.9 million | Up 8.4%; 4.0% versus 3.9% of revenue |
| Operating income (loss) | $(1.9) million | $7.5 million | Operating margin approximately (1.0)% versus 4.3% |
| Net loss attributable to RadNet common stockholders | $(4.6) million | $(12.4) million | Loss per share $(0.11) versus $(0.31) |
| Adjusted EBITDA (non-GAAP) | $20.2 million | $27.7 million | Down 27.0%; see company reconciliation and definition |
| Cash from operating activities | $17.5 million | $(4.9) million | Improved by $22.3 million |
| Capital expenditures | $19.8 million | $17.0 million | Cash used for property and equipment |
Revenue growth included 96,000 more imaging procedures (1.212 million versus 1.116 million). Same-center service fee revenue fell 0.8%, which management attributed to adverse East Coast weather; acquired or divested centers contributed $7.8 million of service fee revenue in Q1 2015, versus $0.3 million in Q1 2014. Operating costs grew faster than revenue: cost of operations excluding depreciation and amortization rose 16.5% to $168.9 million. Management cited higher staffing and professional reading fees, stock-based compensation, medical supplies, rent, and other operating costs. Q1 is typically the company’s seasonally weakest quarter, in part due to winter weather and patients’ high-deductible plan costs resetting in January.
Liquidity, debt, and balance sheet
- At March 31, cash was $154,000, accounts receivable was $153.3 million, and working capital was $61.7 million, up from $58.7 million at year-end 2014.
- Term loans had $574.6 million face value and $563.3 million carrying value after discounts. The revolving facility had $24.7 million outstanding. Total liabilities were $735.9 million; total equity was $6.5 million.
- Interest expense was $10.0 million, down 15.1%, primarily reflecting retirement of the former $200 million senior notes in 2014. The second-lien term loan carried an 8% rate at March 31, 2015. First-lien term loans amortize at approximately $5.2 million quarterly; the second-lien loan has no scheduled amortization and matures in 2021.
- Management said cash flow from operations, available cash, and available senior secured borrowing capacity should meet liquidity needs, while noting financing needs depend on factors beyond its control. RadNet reported compliance with financial covenants at March 31, 2015.
Outlook, risks, and other notable items
- No specific financial guidance or quantified forward outlook is provided in the filing. Management expects to fund working capital, capital expenditures, debt service, and any acquisitions through operating cash flow and borrowings, potentially including additional debt or equity.
- Management estimated that the 2014 debt refinancing increased annual scheduled term-loan amortization by $16.8 million, partly offset by approximately $5.0 million of annual interest savings; it expected to fund the net increase from operating cash flow.
- After quarter-end, RadNet acquired substantially all assets of New York Radiology Partners on April 1 for $31.4 million ($29.8 million cash and a $1.6 million note), borrowing $29.8 million under its revolver. On April 30, it borrowed $75.0 million in incremental first-lien term loans, using proceeds to repay revolver borrowings, fund the balance sheet, and pay approximately $1 million of fees and expenses.
- Meaningful-use incentives contributed $3.3 million of non-operating income, versus $1.8 million in Q1 2014. Recognition depends on Medicare acceptance of provider attestations.
- Key risks include substantial debt and required amortization, dependence on external financing, reimbursement-rate changes, patient collection and bad-debt trends, high fixed costs, and possible effects of value-based payment models. The filing notes that value-based care could reduce revenue and require investment in IT and analytics. Management said ordinary-course litigation was not expected to have a material adverse impact.
- Management reported disclosure controls as effective and no material change in internal control over financial reporting during the quarter. No financial covenant default or unregistered equity sales were reported.
Most important facts for investors to verify
- Whether operating costs can moderate and restore positive operating margins, given revenue growth alongside a Q1 operating loss and lower Adjusted EBITDA.
- Whether operating cash flow can consistently cover capital spending, scheduled debt amortization, interest, and acquisition needs; quarter-end cash was very low.
- Debt balances, interest-rate exposure, covenant headroom, and the post-quarter effects of the NYRP acquisition and $75 million incremental term borrowing.
- Whether capitation growth persists and how reimbursement changes, patient deductibles, and bad-debt experience affect revenue and collections.
- The terms, integration, and expected contribution of the NYRP acquisition; the filing provides no quantified forecast of its financial impact.